Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2022, representing a year-over-year growth of 15%[1]. - The company's operating revenue for the first half of 2022 was ¥115,394,434.94, representing a year-on-year increase of 20.50% compared to ¥95,765,463.55 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2022 was ¥39,142,549.54, an increase of 12.71% from ¥34,728,250.67 in the previous year[19]. - The net cash flow from operating activities increased by 52.33% to ¥46,632,408.23, compared to ¥30,612,806.46 in the same period last year[22]. - The company achieved a main business revenue of 110.15 million yuan, an increase of 19.02% compared to the same period last year[32]. - The company reported revenue of 4.41 million yuan for its thoracic surgery product, PEEK sternum fixation belt, during the reporting period, reflecting a growth of 183.63% year-on-year[42]. - The company’s PEEK material neurosurgical products generated revenue of 67.62 million yuan, a growth of 23.99% year-on-year, accounting for 61.39% of the main business revenue[64]. - The company’s titanium material neurosurgical products generated revenue of 36.17 million yuan, reflecting a year-on-year growth of 5.90%[64]. Market Expansion and Product Development - The company has provided a positive outlook for the second half of 2022, projecting a revenue growth of 10% to 15% based on current market trends[1]. - New product development includes the launch of a next-generation titanium cranial repair product, expected to enhance market competitiveness and drive sales growth[1]. - The company is expanding its market presence, targeting new regions in Asia, with plans to enter three additional countries by the end of 2022[1]. - A strategic acquisition of a smaller medical device firm is in progress, aimed at enhancing the company's product portfolio and technological capabilities[1]. - The company is expanding its product lines in neurosurgery and thoracic surgery, with plans to extend into oral and spinal fields[32]. - The company is pursuing registration for its PEEK cranial repair and fixation products in international markets, including the United States, Mexico, Brazil, and Argentina, to expand its business[44]. Research and Development - The company has allocated 100 million RMB for research and development in innovative medical technologies over the next year[1]. - The R&D expenditure as a percentage of operating revenue was 5.21%, a decrease of 0.8 percentage points from 6.01% in the previous year[21]. - R&D expenses totaled CNY 6,008,783.71, an increase of 4.41% from CNY 5,755,013.65 in the same period last year, with R&D expenses accounting for 5.21% of total revenue[51]. - The company has applied for a total of 3 new patents during the reporting period, bringing the cumulative total to 47 applications and 40 granted patents[50]. - The company has completed product process validation, design verification, and clinical evaluation for the bio-regenerative material artificial dura mater, with plans to submit an FDA certification application in the second half of the year[49]. Risk Management - The company has identified potential risks related to supply chain disruptions but has implemented strategies to mitigate these risks[1]. - The company faces risks related to new product development failures, market demand changes, and core technology protection, which could adversely affect its long-term competitiveness[74]. - The company is exposed to risks associated with maintaining stable relationships with distributors, which are crucial for sales performance[81]. - The company faces risks related to the implementation of centralized procurement policies, which could significantly impact sales and pricing if products are included in such policies[78]. Shareholder and Governance - The company has commitments from major shareholders and executives regarding share lock-up periods, with specific durations of 12 to 36 months post-IPO[111]. - The company will not transfer or entrust others to manage shares held before the IPO for 36 months from the date of the IPO[116]. - The company’s controlling shareholder has pledged not to interfere with the company's management or infringe on its interests, and will bear compensation responsibilities for any violations[136]. - The company will ensure timely and truthful reporting of shareholding changes by its directors and senior management[121]. - The company has established a share lock-up commitment for core technical personnel, restricting share transfers to no more than 25% of their total holdings annually after the lock-up period[112]. Financial Position - The company's total assets as of June 30, 2022, were ¥597,186,925.13, reflecting a 4.15% increase from ¥573,379,179.06 at the end of the previous year[20]. - The total liabilities increased from ¥61,502,269.25 to ¥83,152,085.46, marking a rise of about 35.2%[195]. - The company's cash and cash equivalents decreased by 34.97% to ¥211,560,715.95, down from ¥325,333,432.06 in the previous year[90]. - The company has made significant investments in long-term equity, with long-term equity investments rising to CNY 84,635,526.88 from CNY 48,239,026.88, an increase of about 75.5%[198].

Financial Performance - Revenue for Q1 2022 reached ¥53,501,448.21, an increase of 30.15% compared to the same period last year[5] - Net profit attributable to shareholders was ¥18,031,944.39, reflecting a growth of 29.25% year-over-year[5] - Net profit excluding non-recurring gains and losses increased by 63.68% to ¥17,721,527.77[5] - Basic earnings per share for the period was ¥0.31, a decrease of 3.13% compared to the previous year[6] - The company achieved a main business revenue of 53.50 million RMB, a year-on-year increase of 30.15%[15] - Operating profit for Q1 2022 was ¥21,243,683.61, up 31.5% from ¥16,128,936.29 in the same period last year[23] - Net profit for Q1 2022 was ¥17,578,386.38, representing a 28.5% increase compared to ¥13,735,757.86 in Q1 2021[24] Cash Flow - Net cash flow from operating activities was ¥15,656,175.96, up 113.71% year-over-year[5] - The increase in operating cash flow was attributed to higher sales revenue and stable cash outflows compared to the previous year[10] - Cash flow from operating activities increased to ¥15,656,175.96 in Q1 2022, compared to ¥7,325,746.34 in Q1 2021, marking a 114.8% rise[26] - The company reported a net cash increase of ¥183,439,754.46 at the end of Q1 2022, down from ¥71,642,038.21 at the end of Q1 2021[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥600,780,145.86, representing a 4.78% increase from the end of the previous year[6] - Total assets as of March 31, 2022, amounted to 600.78 million RMB, compared to 573.38 million RMB at the end of 2021[20] - Total liabilities increased to 81.89 million RMB from 71.98 million RMB year-on-year[20] - The equity attributable to shareholders reached 521.27 million RMB, up from 503.32 million RMB at the end of 2021[20] Research and Development - R&D investment totaled ¥2,481,241.25, down 39.27% compared to the previous year[6] - R&D expenditure as a percentage of revenue was 4.64%, a decrease of 5.30 percentage points year-over-year[6] - Research and development expenses decreased to ¥2,481,241.25 in Q1 2022 from ¥4,085,590.97 in Q1 2021, a reduction of 39.3%[23] - The company’s research project "3D printed PEEK cranial system" received approval for special review, expediting its market entry[16] Revenue Breakdown - Revenue from PEEK material cranial repair fixation products was 31.47 million RMB, growing by 30.43% year-on-year[15] - Revenue from titanium material cranial repair fixation products was 15.90 million RMB, with an 8.73% year-on-year increase[15] - The PEEK material sternum fixation system generated revenue of 2.07 million RMB, a significant increase of 514.11% year-on-year[15] Other Financial Metrics - Total operating costs for Q1 2022 were ¥31,854,707.27, an increase of 18.2% from ¥26,951,005.33 in Q1 2021[23] - The company experienced a decrease in other comprehensive income, reporting a net loss of ¥86,782.24 in Q1 2022 compared to a gain of ¥449,491.56 in Q1 2021[24] - Cash flow from investing activities showed a net outflow of ¥170,936,303.22 in Q1 2022, worsening from a net outflow of ¥27,985,345.84 in Q1 2021[26] Market Activities - The company increased its market promotion efforts, contributing to the rise in revenue[9] - The company completed a 16.67% equity investment in BPA, facilitating the introduction of a wireless intracranial pressure monitor[16]

Financial Performance - The company reported a total revenue of 5,600 million RMB for the year, with a significant increase from 3,016.04 million RMB in the previous year, representing a growth of approximately 86%[71]. - The company's operating revenue for the reporting period was approximately ¥212.55 million, representing a year-on-year increase of 29.54%[92]. - The net profit attributable to shareholders of the listed company rose by 55.83% year-on-year to approximately ¥81.63 million, while the net profit after deducting non-recurring gains and losses increased by 46.34% to approximately ¥66.40 million[21]. - The company's total assets at the end of 2021 were approximately ¥573.38 million, reflecting a 96.70% increase compared to the end of 2020[21]. - The net cash flow from operating activities increased by 78.61% year-on-year, amounting to approximately ¥103.29 million, attributed to the increase in product revenue during the reporting period[23]. - The company's financial expenses decreased significantly by 82.08% due to increased interest income from public offering proceeds[92]. - The company reported a net profit margin of 490.43 million, indicating strong profitability[140]. - The company achieved a total R&D expenditure of ¥16,804,775.34, a decrease of 0.56% compared to the previous year[66]. Dividend and Share Capital - The company plans to distribute a cash dividend of 6.20 RMB per 10 shares, totaling approximately 35.98 million RMB, which represents 44.08% of the net profit attributable to shareholders for 2021[7]. - The total share capital of the company as of the end of the reporting period was 58,027,980 shares[7]. - The company distributed a cash dividend of 0.52 CNY per share, totaling 30,174,549.60 CNY, based on a total share capital of 58,027,980 shares[160]. Corporate Governance - The company has received a standard unqualified audit opinion from its accounting firm[8]. - There are no special arrangements for corporate governance applicable to the company[9]. - The company has confirmed that all board members attended the board meeting[6]. - The company has established internal management systems for subsidiaries, including financial management and internal auditing, to ensure stable operations[163]. - The company emphasizes ESG principles, focusing on product quality, cost reduction, and governance improvements to enhance shareholder value and sustainable development[165]. - The company maintains a transparent governance structure, ensuring compliance with legal requirements and protecting the interests of shareholders and creditors[173]. Market and Product Development - The company plans to continue expanding its market presence and enhancing product offerings, particularly in the neurosurgical sector[23]. - The company is focused on expanding its product lines in neurosurgery and thoracic surgery, while also extending into oral and spinal fields[38]. - The company is actively developing new products, including artificial dura mater and disposable neurosurgical drainage devices, to expand its product line in the cranial repair segment[56]. - The company has established cooperation with over 300 distributors, covering 1,500 hospitals, including 900 tertiary hospitals[33]. - The company is developing a 3D printed PEEK craniofacial system using laser sintering technology, which improves processing efficiency and reduces material waste[55]. Research and Development - The research and development expenditure as a percentage of operating revenue was 7.91%, a decrease of 2.39 percentage points from 10.30% in 2020[23]. - The company has received 7 new patent authorizations during the reporting period, including 3 invention patents and 4 utility model patents, bringing the total to 7 invention patents and 14 utility model patents[36]. - The company has established a dedicated team for intellectual property management, conducting patent searches during new product development to avoid redundant research and investment[184]. - The company has improved the injection molding process for PEEK materials, enhancing production efficiency and reducing material waste[63]. Risks and Challenges - The company faces risks related to new product development and registration failures, which could adversely affect long-term core competitiveness[77]. - There is a risk of supply chain disruption for critical raw materials, particularly PEEK and titanium, which could impact production and sales if suppliers fail to meet quality standards or increase prices[79]. - The company is exposed to risks from centralized procurement policies for high-value medical consumables, which could lead to significant price reductions and impact sales[82]. - The integration of the subsidiary BIOPLATE poses management challenges, and failure to effectively manage this integration could affect profitability[80]. Employee and Management - The company has expanded its workforce by adding 31 new employees, including 8 in R&D and 10 in sales, to strengthen its talent pool[36]. - The number of R&D personnel increased to 41, accounting for 20% of the total workforce, up from 19% in the previous year[73]. - Total compensation for all directors, supervisors, and senior management at the end of the reporting period amounted to 490.43 million[147]. - The company has a strong focus on continuous product and process innovation, having transitioned several original technologies into industrial applications since 2008[75]. Future Outlook - Future outlook suggests continued growth with a focus on expanding user data and market presence[140]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% based on new product launches and market expansion strategies[143]. - The company plans to enhance its market share in South America and the Asia-Pacific region by promoting PEEK and titanium neurosurgical products[128]. - The company aims to enhance customer engagement through innovative solutions and services[140].

Financial Performance - The company's operating revenue for Q3 2021 was ¥55,289,121.77, representing a year-over-year increase of 26.92%[5] - The net profit attributable to shareholders for Q3 2021 was ¥27,175,982.55, reflecting a 50.52% increase compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥22,599,759.69, showing a significant increase of 99.49% year-over-year[5] - Total revenue for the first three quarters of 2021 reached ¥151,054,585.32, a 33.6% increase compared to ¥113,069,140.66 in the same period of 2020[24] - Net profit for the third quarter of 2021 was ¥61,511,761.41, compared to ¥40,365,225.30 in the same quarter of 2020, representing a 52.3% increase[25] - The net profit attributable to the parent company shareholders for Q3 2021 was ¥61,904,233.22, an increase from ¥41,485,401.32 in Q3 2020, representing a growth of approximately 49.3%[26] - The total comprehensive income attributable to the parent company for Q3 2021 was ¥61,961,081.14, compared to ¥41,215,914.54 in Q3 2020, reflecting a growth of 50.5%[26] Assets and Liabilities - The total assets at the end of Q3 2021 reached ¥541,783,624.50, which is an 85.86% increase compared to the end of the previous year[6] - The total assets of the company as of the end of the third quarter of 2021 amounted to ¥541,783,624.50, significantly higher than ¥291,506,419.87 at the end of the same period in 2020[20] - Current assets totaled ¥347,014,032.66, compared to ¥143,318,132.92 in the previous year, indicating a substantial growth[20] - The company's total liabilities reached ¥59,635,877.98, up from ¥48,458,340.54 in the same period last year[21] - The equity attributable to shareholders increased by 97.94% year-over-year, amounting to ¥484,025,720.10[6] - The equity attributable to shareholders increased to ¥484,025,720.10 from ¥244,534,057.40 year-over-year[21] Earnings and Cash Flow - The basic earnings per share for Q3 2021 was ¥0.47, a 14.63% increase compared to the same period last year[6] - The basic and diluted earnings per share for Q3 2021 were both ¥1.24, compared to ¥0.95 in Q3 2020, indicating a year-over-year increase of 30.3%[27] - Cash flow from operating activities for the first three quarters of 2021 was ¥68,132,297.09, up from ¥38,624,149.10 in the same period of 2020, reflecting a growth of 76.4%[27] - Total cash inflow from operating activities was ¥188,256,785.37, compared to ¥137,841,460.37 in the previous year, marking an increase of 36.5%[27] - The net cash flow from financing activities for Q3 2021 was ¥183,738,361.81, a significant improvement from a net outflow of ¥3,919,836.68 in Q3 2020[28] Research and Development - Research and development expenses totaled ¥2,473,667.20 for Q3 2021, which is a decrease of 19.89% compared to the same period last year[6] - The proportion of R&D expenses to operating revenue was 4.47%, down by 2.62 percentage points year-over-year[6] - Research and development expenses for the third quarter of 2021 were ¥8,228,680.85, slightly down from ¥8,301,936.76 in the previous year[25] - The important research product, 3D printed PEEK craniofacial system, is undergoing clinical trials in five hospitals, with smooth progress in its development registration[16] Production and Operations - The new factory project for the production and research of three types of implantable medical devices is under orderly construction, with the main production and office areas completed[15] - The company has obtained the medical device production license for the new factory, which is expected to enhance production capacity and efficiency[15] - The company plans to complete the relocation to the new factory and related license changes by the end of the year[15] Revenue Breakdown - The company achieved a main business revenue of 146.91 million RMB, a year-on-year increase of 35.07%, and a net profit attributable to shareholders of 61.90 million RMB, up 49.22% year-on-year[15] - Revenue from PEEK material repair products reached 58.21 million RMB, a year-on-year growth of 70.58%[15] - The PEEK material skull fixation products generated revenue of 30.15 million RMB, reflecting a 23.80% increase compared to the same period last year[15] - The revenue from titanium skull repair products was 13.50 million RMB, showing a year-on-year growth of 16.84%[15] - The revenue from titanium skull fixation products was 38.46 million RMB, with a year-on-year increase of 5.86%[15] - The revenue from PEEK material sternum fixation system reached 3.19 million RMB, a significant increase of 1560.52% year-on-year[15]

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, achieving a total of RMB 500 million, representing a 25% year-over-year growth[1]. - The company's operating revenue for the first half of 2021 was ¥95,765,463.55, representing a year-on-year increase of 37.77% compared to ¥69,508,601.75 in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2021 was ¥34,728,250.67, an increase of 48.22% from ¥23,430,603.89 in the previous year[19]. - The net cash flow from operating activities increased by 62.03% to ¥30,612,806.46, up from ¥18,892,747.28 in the same period last year[20]. - The total assets at the end of the reporting period were ¥542,225,029.41, reflecting an 86.01% increase from ¥291,506,419.87 at the end of the previous year[20]. - The net assets attributable to shareholders increased by 86.84% to ¥456,896,735.67 from ¥244,534,057.40 at the end of the previous year[20]. - Basic earnings per share for the first half of 2021 were ¥0.76, a 40.74% increase from ¥0.54 in the same period last year[21]. - The company achieved a weighted average return on equity of 13.26%, an increase of 1.8 percentage points from 11.46% in the previous year[21]. Market Expansion and Product Development - The company has provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 30% based on current market trends and demand[1]. - New product development includes the launch of a cutting-edge titanium cranial repair product, expected to contribute an additional RMB 100 million in revenue by the end of the year[1]. - The company is expanding its market presence, targeting new regions in Southeast Asia, with plans to establish partnerships with local distributors[1]. - A strategic acquisition of a smaller competitor is in progress, which is anticipated to enhance the company's product offerings and market share by 10%[1]. - The company aims to expand its product lines in neurosurgery and thoracic surgery while also venturing into oral and spinal fields[27]. - The company is actively developing multiple research projects, including artificial dura mater and disposable neurosurgical drainage devices, to expand its product line[52]. Research and Development - The company has invested RMB 50 million in R&D for innovative medical technologies, aiming to improve operational efficiency and product quality[1]. - The research and development expenditure as a percentage of operating revenue was 6.01%, down 1.49 percentage points from 7.50% in the previous year[21]. - The company achieved a total R&D investment of ¥5,755,013.65, representing a 10.38% increase compared to the previous period's ¥5,213,960.27[43]. - The company developed a personalized skull defect repair technology using PEEK materials, enhancing customization and aesthetic outcomes compared to traditional titanium materials[40]. - The company has implemented a 3D printing technology for producing PEEK plates, which improves material efficiency and processing accuracy[40]. Risks and Challenges - No significant risks were identified during the reporting period that could impact the company's operations or financial performance[1]. - The company faces risks related to the high technical difficulty and lengthy development cycles of Class III medical devices, which could impact long-term competitiveness if registration fails[60]. - There is a risk of supply chain disruption for critical raw materials like PEEK, which could affect production and sales if suppliers cannot meet quality standards or increase prices[61]. - The penetration rate of PEEK cranial repair products is currently low in the domestic market, and any obstacles to market adoption could negatively impact sales growth[61]. - Integration risks exist following the acquisition of BIOPLATE, as effective management is crucial for maintaining operational performance and profitability[62]. Financial Position and Assets - Cash and cash equivalents at the end of the period reached ¥303,048,222.23, accounting for 55.89% of total assets, a significant increase of 226.55% compared to the previous year[75]. - The total liabilities of the company as of June 30, 2021, were RMB 87,117,450.44, compared to RMB 48,458,340.54 at the end of 2020, reflecting an increase of around 80%[178]. - The equity attributable to the parent company reached RMB 456,896,735.67, up from RMB 244,534,057.40, which is an increase of approximately 87%[178]. - The company's inventory as of June 30, 2021, was RMB 40,790,599.14, compared to RMB 36,365,569.61 at the end of 2020, showing an increase of about 12%[176]. Shareholding and Corporate Governance - The company has made commitments regarding shareholding restrictions for key personnel, including Hu Liren, who is restricted from transferring shares for 36 months post-IPO[94]. - The company will ensure compliance with regulations regarding shareholding and changes in shareholding for directors and senior management[106]. - The company has established a profit distribution policy in accordance with relevant laws and regulations, which will be strictly followed post-listing[130]. - The controlling shareholder commits to increase stock holdings according to the stock price stabilization plan after conditions are met[123]. Compliance and Environmental Responsibility - The company meets the emission standards for industrial waste gas and has proper disposal measures for hazardous waste[90]. - There have been no administrative penalties related to environmental issues during the reporting period[91]. - The company has not disclosed any additional environmental information or measures taken to reduce carbon emissions[92].